tbuckley/cabot-search huggingface dataset:
Outcomes of ASCT for cardiac AL-amyloidosis and cardiac light chain deposition disease.
Authors: Al-Ola A. Abdallah, Shebli Atrash, Aziz Bakhous, Daisy Alapat, Maurizio Zangari
Journal: Journal of Clinical Oncology (2015)

7035 Background: Melphalan based autologous stem cell transplant (ASCT) can reverse the progression of systemic amyloidosis and light chain deposition disease (LCDD) in selected patients. However, role of ASCT in patients with cardiac involvement due to amyloidosis and LCDD is still unclear Methods: Our database at Myeloma Institute for Research and Therapy identified 53 patients, with biopsy proven cardiac amyloidosis and cardiac LCDD between January 2004 and December 2012. A retrospective analysis was performed to identify difference in outcomes between the patients who received ASCT or chemotherapy (CTX). Results: Out of these 53 patients, 5 patients were excluded because they did not receive treatment for plasma cell dyscrasia. 37 patients received ASCT and 11 patients received CTX, such as bortezomib, lenalidomide, low dose melphalan, interferon, and cyclophosphamide 66% (n = 32) patients had elevated Brain natriuretic peptide > 500 Pg/ml, 40% (n = 19) had elevated lactate dehydrogenase > 190, 15% (n = 7) had elevated levels of beta-2-microglobulin > 3.5 mg/dl, 44% (n = 21) had elevated creatinine > 1.5 mg/dl at the time of diagnosis. Echocardiogram showed speckled appearance in 19% (n = 9) patients, diastolic dysfunction was present in 58% (n = 28), systolic dysfunction was present in 27% (n = 13), 62% (n = 30) had increase diastolic intra-ventricular septum (IVSD) thickness measuring > 1.3 cm. On a long term follow up, the group of patients with CA who received ASCT had median survival of 4.53 year compared to median survival of 1.85 years for those who received CTX (p = 0.69). 35% (n = 13) patients had life threatening events including severe congestive heart failure, arrhythmias and severe infections in the first 12 months of treatment with ASCT Conclusions: CA is aggressive disease with median survival of 8 months. Eligibility for ASCT in CA varies across institutions. Our single institution experience shows that patients with CA might benefit from ASCT with improvement in median survival as compared to those who received CTX. However ASCT should be further investigated with focused evaluation prior treatment, supportive care during and after treatment to decrease the risk of life threatening events.
THU-448-Multicentric prospettive study of validation of angiogenesis-related gene polymorphisms in hepatocellular carcinoma patients treated with sorafenib: Interim analysis of INNOVATE study
Authors: Andrea Casadei Gardini, Giorgia Marisi, Luca Faloppi, Vincenzo Dadduzio, Emanuela Scarpi, Luca Ielasi, Francesco Foschi, Caterina Vivaldi, Giovanni Cardellino, Emiliano Tamburini, Marianna Siletta, Francesca Negri, Paola Ulivi, Mario Domenico Rizzato, Laura Gramantieri, Fabio Conti, Lorenzo Fornaro, Annamaria Porfiello, Britt Rudnas, Daniele Santini, Alessandro Leonetti, Nicola Silvestris, Sabina Murgioni, Francesca Fornari, Irene Pecora, Antonella Argientiero, Sara Lonardi, Stefano Cascinu, Mario Scartozzi
Journal: Journal of Hepatology (2019)
Measuring What Matters in Diabetes
Authors: Rene Rodriguez-Gutierrez, Rozalina G. McCoy
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 144: Cardiac Expression of Mitochondrial Acetyltransferase Gcn5l1 Contributes to Ischemia-Reperfusion Injury and Alters Mitochondrial Energetics After Injury
Authors: Janet R Manning, Dharendra Thapa, Manling Zhang, Michael W Stoner, Iain Scott
Journal: Circulation Research (2017)

Introduction: The increasing global burden of ischemic heart disease demands a closer examination of the mechanisms by which myocardial reperfusion produces injury to initiate long-term heart failure. Reactive oxygen species (ROS) generated after ischemia reperfusion (IR), in conjunction with the dysfunction of mitochondrial metabolic enzymes, have been identified as a primary mediator of cardiac reperfusion injury. The acetylation of mitochondrial proteins, regulated by opposing actions of NAD + -dependent sirtuin deacetylases and the recently identified mitochondrial acetyltransferase GCN5L1, has emerged as a key point of intersection between nutrient status and mitochondrial protein function in cardiomyoctyes. This makes the association between acetylation and ROS production an important topic of investigation. Intriguingly, global protein acetylation was recently reported to be upregulated in the hearts of human patients with ischemic heart failure. Despite this, it remains unknown whether GCN5L1 acetyltransferase activity plays a role in the regulation of metabolic proteins during IR injury. Hypothesis: Cardiac deletion of the acetyltransferase GCN5L1 reduces the acetylation of mitochondrial proteins during IR, reducing aberrant activity and preventing ROS production. Methods: Isolated work-performing hearts from cardiac-specific inducible GCN5L1 knockout mice were subjected to global ischemia and reperfusion. Contractility (+/- dP/dT) of the left ventricle was measured throughout as an index of post IR functional recovery. Tissue damage was assessed by measuring the release of lactate dehydrogenase and post-reperfusion staining of viable tissue with triphenyltetrazolium chloride. Acetylation levels of mitochondrial proteins were measured during IR using immunoblotting of homogenized hearts, which were also used to evaluate ROS production. Results and Conclusions: Mitochondrial acetylation was decreased in GCN5L1 hearts compared to WT, coinciding with improved post-IR recovery. We therefore conclude that acetylation of mitochondrial proteins by the acetyltransferase GCN5L1 is an important regulatory mechanism of IR-induced, ROS-mediated damage.
SAT-059-Prevalence and clinical characteristics of malnutrition in cirrhosis according to new EASL practice guidelines
Authors: Dae Won Jun, Jinhwa Park, Bo-Kyeong Kang, Mi Mi Kim, Jaeyoon Jeong, Joo Hyun Sohn, Hyunwoo Oh, Hyo Young Lee, Sang Bong Ahn, Yong Kyun Cho, Dong Hee Koh
Journal: Journal of Hepatology (2019)
FRI-162-Prime-boost vaccination strategies using chimpanzee-adeno and MVA viral vectored vaccines encoding multiple HBV antigens (CPmutS) and class II invariant chain molecular adjuvants induces robust T-cell and anti-HBs antibody response in mice
Authors: Tamsin Cargill, Timothy Donnison, Azim Ansari, Mala Maini, Tom Evans, Eleanor Barnes, Senthil Kumar Chinnakannan
Journal: Journal of Hepatology (2019)
FRI-035-Clinical outcomes associated with additional fibrate treatment in UDCA-refractory PBC patients: A multicenter study
Authors: Jeonghoon Lee, Sungwon Chung, Cheol-Hyung Lee, Minseok Albert Kim, Galam Leem, SunWoong Kim, Young Chang, Hyo Young Lee, Jun Sik Yoon, Jun Yong Park, Yun Bin Lee, Eun Ju Cho, Su Jong Yu, Yoon Jun Kim, Jung-Hwan Yoon
Journal: Journal of Hepatology (2019)
Cardiovascular Risk and Risk Factor Management in Type 2 Diabetes Mellitus
Authors: Alison K. Wright, Evangelos Kontopantelis, Richard Emsley, Iain Buchan, Mamas A. Mamas, Naveed Sattar, Darren M. Ashcroft, Martin K. Rutter
Journal: Circulation (2019)

Background: With recent changes in the United Kingdom’s clinical practice for diabetes mellitus care, contemporary estimates of sex disparities in cardiovascular risk and risk factor management are needed. Methods: In this retrospective cohort study, using the Clinical Practice Research Datalink linked to hospital and death records for people in England, we identified 79 985 patients with incident type 2 diabetes mellitus (T2DM) between 2006 to 2013 matched to 386 547 patients without diabetes mellitus. Sex-stratified Cox models were used to assess cardiovascular risk. Results: Compared with women without T2DM, women with T2DM had a higher cardiovascular event risk (adjusted hazard ratio, 1.20 [95% confidence interval, 1.12–1.28]) with similar corresponding data in men (hazard ratio, 1.12 [1.06–1.19]), leading to a nonsignificant higher relative risk in women (risk ratio, 1.07 [0.98–1.17]). However, some important sex differences in the management of risk factors were observed. Compared with men with T2DM, women with T2DM were more likely to be obese, hypertensive, and have hypercholesterolemia, but were less likely to be prescribed lipid-lowering medication and angiotensin-converting enzyme inhibitors, especially if they had cardiovascular disease. Conclusions: Compared with men developing T2DM, women with T2DM do not have a significantly higher relative increase in cardiovascular risk, but ongoing sex disparities in prescribing should prompt heightened efforts to improve the standard and equity of diabetes mellitus care in women and men.
Continuum of care in advanced non-small lung cancer patients (ANSCLC).
Authors: Zhasmina Mihaylova, Vera Georgieva Megdanova, Veneta Petrova, Dobromira Petkova-Nelova, Albena Fakirova, Hristo Dinev
Journal: Journal of Clinical Oncology (2015)

e19132 Background: Background Randomized studies proved that maintenance treatment (MT) significantly prolong survival. The study aimed to search the impact MT on survival among baseline clinical, biological and laboratory factors in patients (pts) with ANSCLC treated with first line systemic therapy (FLT). Methods: Methods 34 clinical, biological and laboratory parameters from ANSCLC pts admitted for FLT were retrospectively collected. ANOVA and Cox-regression analysis were used. Statistics was performed using SPSS 9,0 software. All measurements were two-sided and p < 0.05 was consider statistically significant. Results: Results Analyzed pts were114 with mean age 58.9; Distribution of histo-types was squamo/adeno/large cell/others 31/69/9/6. Platinum-based FLT received 91.2% and anti-EGFR FLT - 10 pts. MT received 25 pts with mean duration 6.5 months (mo) (1-25).Almost a half of pts (49.1%) were treated with 2 or more treatment lines after MT. Tabl.1 ANOVA analysis ANOVA - factors PFS mo p OS mo p PS 0-1/2 8.96/4.6 .001 15.2/7.8 .03 Stage IIIA/IIIB/IV 13.5/5.8/7.5 .015 22.2/9.5/12.8 .045 Smoking ever/never 6.68/11.8 .001 11.08/20.9 .0001 Weight loss > / < 5% in 6 mo 5.7/9.9 .004 9.6/14.3 .042 Response rate to FLT PR/SD/PD 11.6/12.9/4.98 .0001 20.03/19.05/9.28 .0001 MT yes/ no 13.5/6.6 .0001 22.3/11.7 .0001 Number of treatment lines 1/ > 2 6.4/9.3 .019 8.7/17.9 .0001 Neutrophil to Lymphocyte ratio (NLR) > 3.57/ < 3.57 6.5/10.7 .011 11.5/13.4 .102 Platelet to Lymphocyte Ratio (PLR) > 188/ < 188 6.2/10.7 .002 11.1/16.9 .037 C-Reactive Protein > 20.4/ < 20.4 6.3/8.7 .09 8.8/13.7 .011 In Cox regression model from all ANOVA factors entered (Tabl.1) for PFS, significance retained only MT (0.001) and RR with borderline p of 0.08. In the model for OS, MT is the only significant factor (0.008) with smoking history (0.056) and number of treatment lines (0.051) reaching borderline values. Conclusions: Conclusions In pts with ANSCLC factors of systemic inflammatory response (CRP, NLR, PLR) and clinical factors (PS, WL) should be monitored because of their impact on prognosis. MT is an independent prognostic factors for PFS and OS. Long MT and more than one treatment lines should be considered as continuum of care and evidently prolongs survival times of ANSCLC pts.
Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study
Authors: Joan L. Walker, Mark F. Brady, Lari Wenzel, Gini F. Fleming, Helen Q. Huang, Paul A. DiSilvestro, Keiichi Fujiwara, David S. Alberts, Wenxin Zheng, Krishnansu S. Tewari, David E. Cohn, Matthew A. Powell, Linda Van Le, Susan A. Davidson, Heidi J. Gray, Peter G. Rose, Carol Aghajanian, Tashanna Myers, Angeles Alvarez Secord, Stephen C. Rubin, Robert S. Mannel
Journal: Journal of Clinical Oncology (2019)

To evaluate the impact of two different intraperitoneal (IP) chemotherapy regimens on progression-free survival (PFS) among women with newly diagnosed advanced ovarian carcinoma.
Group A rotavirus surveillance before vaccine introduction in Italy, September 2014 to August 2017
Authors: Giovanni Ianiro, Roberto Micolano, Ilaria Di Bartolo, Gaia Scavia, Marina Monini
Journal: Eurosurveillance (2019)

IntroductionGroup A rotaviruses (RVA) are the leading cause of acute gastroenteritis (AGE) in young children, causing ca 250,000 deaths worldwide, mainly in low-income countries. Two proteins, VP7 (glycoprotein, G genotype) and VP4 (protease-sensitive protein, P genotype), are the basis for the binary RVA nomenclature. Although 36 G types and 51 P types are presently known, most RVA infections in humans worldwide are related to five G/P combinations: G1P[8], G2P[4], G3P[8], G4P[8], G9P[8].AimThis study aimed to characterise the RVA strains circulating in Italy in the pre-vaccination era, to define the trends of circulation of genotypes in the Italian paediatric population.MethodsBetween September 2014 and August 2017, after routine screening in hospital by commercial antigen detection kit, 2,202 rotavirus-positive samples were collected in Italy from children hospitalised with AGE; the viruses were genotyped following standard European protocols.ResultsThis 3-year study revealed an overall predominance of the G12P[8] genotype (544 of 2,202 cases; 24.70%), followed by G9P[8] (535/2,202; 24.30%), G1P[8] (459/2,202; 20.84%) and G4P[8] (371/2,202; 16.85%). G2P[4] and G3P[8] genotypes were detected at low rates (3.32% and 3.09%, respectively). Mixed infections accounted for 6.49% of cases (143/2,202), uncommon RVA strains for 0.41% of cases (9/2,202).ConclusionsThe emergence of G12P[8] rotavirus in Italy, as in other countries, marks this genotype as the sixth most common human genotype. Continuous surveillance of RVA strains and monitoring of circulating genotypes are important for a better understanding of rotavirus evolution and genotype distribution, particularly regarding strains that may emerge from reassortment events.
Metformin +/- cyclic fasting mimicking diet in combination with platinum-pemetrexed chemotherapy for advanced LKB1 inactive lung adenocarcinoma: The FAME trial
Authors: G. Galli, D. Signorelli, C. Vernieri, M. Ganzinelli, M. Moro, A. Fabbri, E. Tamborini, M. Marabese, E. Caiola, M. Broggini, L. Hollander, R. Gallucci, C. Gavazzi, A.M. Rizzo, P. Corsetto, G. Pruneri, F. de Braud, G. Sozzi, V. Torri, M.C. Garassino
Journal: Annals of Oncology (2019)

Background: LKB1 inactive (LKB1i) lung adenocarcinoma (LA) has an aggressive behavior and is resistant to immunotherapy (IO). LKB1i cells are vulnerable to nutrient starvation. Based on preclinical data showing a synergy cisplatin-metformin, we hypothesized that combining platinum-based chemotherapy (CT) with metformin +/- a calorie-restricted, low-carbohydrate, low-protein diet known as Fasting Mimicking Diet (FMD) may improve the efficacy of CT in patients (pts) with LKB1i LA. Trial design: FAME is a monocentric, open label, double arm, non comparative, randomized, single stage, pick-the-winner phase II trial. Primary objective is Progression Free Survival (PFS), evaluated in comparison with a historical cohort of pts treated with CT. Secondary objectives consist in studying experimental treatment toxicity, response rate, overall survival, metabolic changes in blood, urine and stool, correlation between LKB1 mutation status and LKB1 protein expression. Main inclusion criteria are: advanced LKB1i LA, absence of EGFR mutations and ALK/ROS1 rearrangements, PDL1 expression < 50%, performance status 0-1. Main exclusion criteria are: body mass index <20 kg/m2, weight loss ≥5% in the previous 3 months, diabetes mellitus, active brain metastases, baseline fasting glucose ≤65 mg/dL, arterial pO2 <70 mmHg, high blood lactates. Eligible pts will be randomized 1:1 to up to 4 cycles of platinum-pemetrexed CT + metformin, or up to 4 cycles of platinum-pemetrexed CT + metformin + FMD. After 4 cycles, stable/responding pts will continue pemetrexed + metformin until progression or toxicity. Forty-one pts per arm will be necessary to identify a 4.4 mos increase in median PFS. Brookmeyer-Crowley test will be used with an α tail of .15 and a power of .8 mos. Assuming a dropout rate of 5%, the number of pts to enroll will be 88. Clinical trial identification: NCT03709147, first posted on 17 October 2018; EudraCT: 2018-000788-95. Legal entity responsible for the study: Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. Funding: AIRC (Associazione Italiana per la Ricerca sul Cancro) Investigator Grant 2017. Disclosure: All authors have declared no conflicts of interest.
PS-013-Evaluation of serological markers of extracellular matrix remodeling in primary sclerosing cholangitis
Authors: Lasse Langholm, Christine Zhang-Hagenlocher, Robert Voitl, Petra Kloeters-Plachky, Peter Sauer, Karl Heinz Weiss, Tina Manon-Jensen, Christian Rupp
Journal: Journal of Hepatology (2019)
SAT-275-Interleukin-32 as a novel NAFLD biomarker in PNPLA31148M variant carriers
Authors: Guido Alessandro Baselli, Paola Dongiovanni, Raffaela Rametta, Marica Meroni, serena pelusi, Marco Maggioni, Sara Badiali, Piero Pingitore, Tiziana Montalcini, Giorgio Rossi, Daniele Prati, Silvia Fargion, Rosellina Mancina, Stefano Romeo, Luca Valenti
Journal: Journal of Hepatology (2019)
Evidence to contradict “substantial” forced organ harvesting from prisoners in China is lacking, tribunal hears
Authors: Richard Hurley
Journal: BMJ (2019)

The Chinese state has not responded to repeated invitations to give evidence to an independent tribunal in London that is considering allegations of forced organ harvesting from prisoners in China, the tribunal’s chair said at a second round of public hearings held on 6 and 7 April 2019.

“Despite every effort to find an analysis contrary to the thrust of the evidence no such analysis has been provided,” said the chair, Geoffrey Nice QC.

The tribunal’s seven strong panel is aiming to establish whether, beyond reasonable doubt, the Chinese state or state approved entities have committed criminal offences under international law.

Nice, who also led the prosecution of the former Yugoslav president Slobodan Milosevic in the Hague, emphasised that the tribunal will continue to welcome all pertinent evidence until it issues its final judgment, expected on 17 June 2019.1

Twenty witnesses and experts including refugees from China, doctors, academics, and journalists gave evidence in London in April to the Independent Tribunal into Forced Organ Harvesting from Prisoners …
FRI-092-Metamizole as a leading cause of drug-induced liver injury
Authors: Marcial Sebode, Martin Reike-Kunze, Sören Alexander Weidemann, Roman Zenouzi, Johannes Hartl, Moritz Peiseler, Timur Liwinski, Lisa Schulz, Christina Weiler-Normann, Ansgar Lohse, Christoph Schramm
Journal: Journal of Hepatology (2019)
THU-019-Impact of metabolic stress on the pathogenesis of autoimmune liver disease in subjects bearing missense variant of negative immune regulator Lnk/Sh2b3
Authors: Taizo Mori, Sachio Yoshio, Michitaka Matsuda, Sakamoto Yuzuru, Tomonari Shimagaki, Hironari Kawai, Yosuke Osawa, Tatsuya Kanto
Journal: Journal of Hepatology (2019)
Sexual and marital dysfunction in women with gynecologic cancer: A multi-institutional, cross-sectional trial.
Authors: Saketh Guntupalli, Dina Flink, Jeanelle Sheeder, Jennifer Leifermann, Ana Isabel Tergas, Yevgenia Ioffe, Jason Dennis Wright, Kian Behbakht
Journal: Journal of Clinical Oncology (2015)

9592 Background: Sexual dysfunction is a serious issue for women with gynecologic cancer. This study examines sexual function following cancer treatment and its impact on marital relationships. Methods: A multi-institutional study of women with gynecologic cancer was conducted with a 181item survey of instruments to assess sexual/marital dysfunction. Sexual dysfunction was measured by change in the Female Sexual Function Index (FSFI). A significant decline in sexual function was determined to be 7.6 point decrease using a Reliable Change Index Statistic (RCIS). Marital relationships were assessed using Intimate Bond Measure (IBM). Standard statistical analyses were used. Results: A total of 290 women were enrolled. Cancer diagnoses included uterine/endometrial (41%), ovarian (37%) cervical/other (22%). Treatments included surgery (92%), chemotherapy (62%), and radiation (30%). Among all women, sexual function declined from a score of 23.2±11.2 prior to diagnosis to 15.2±10.2 after treatment (P< 0.001) and sexual activity decreased from 6.1±6.8 to 2.6±4.9 times/month following treatment (P< 0.001). Sexual dysfunction after treatment was associated with younger age (51.8±12.2 to 57.3±12.1, P= 0.004), being premenopausal (27% vs 13.5%, OR 2.38, 95%CI 1.23-4.71), chemotherapy (69.8% v 51.9%, OR 2.05, 95%CI 1.10-3.84), and being in a committed relationship (97.3% vs 82.7%, OR 7.43, 95%CI 1.67-33.11). IBM scores, relationship length, surgery and radiation therapies, cancer site diagnosis/stage and race were not associated with sexual dysfunction. Women with sexual dysfunction reported decreased sexual activity (Δ5.3±4.8 vs Δ2.1±3.8, P< 0.001) and increased relationship counseling, 13.7% vs 4.9%, (OR 3.11, 95%CI 1.02-9.53) compared to those with no impairment. Conclusions: Women with gynecologic cancer are at significant risk for sexual dysfunction. Young, premenopausal women, chemotherapy, and women in committed relationships are at particularly risk for these issues. Patients with sexual dysfunction reported greater decline in sexual activity and sought counseling following treatment. Practitioners should address these issues and engage patients during treatment.
FRI-373-Mismatch in C-locus Eplets between donor and recipient as independent factor of acute T-cell mediated rejection in liver transplantation
Authors: Sandra Guiral, David San Segundo, Antonio Cuadrado, Angela Puente Sanchez, Fernando Casafont, Jose Ignacio Fortea, Marcos López-Hoyos, Javier Crespo, Emilio Fabrega
Journal: Journal of Hepatology (2019)
FRI-403-Impact on post liver transplant outcomes of response to treatment with terlipressin and albumin in patients with hepatorenal syndrome
Authors: Elia Vettore, Salvatore Piano, Marta Tonon, Antonietta Romano, Carmine Gambino, Eleonora Bertoli, Silvano Fasolato, Giacomo Zanus, Patrizia Boccagni, Patrizia Burra, Umberto Cillo, Paolo Angeli
Journal: Journal of Hepatology (2019)
Notes from the Field: Multistate Coccidioidomycosis Outbreak in U.S. Residents Returning from Community Service Trips to Baja California, Mexico — July–August 2018
Authors: Mitsuru Toda, Francisco J. Gonzalez, Maureen Fonseca-Ford, Patrick Franklin, Melinda Huntington-Frazier, Bruce Gutelius, Vance Kawakami, Kristy Lunquest, Stephanie McCracken, Kathleen Moser, Hanna Oltean, Adam J. Ratner, Chelsea Raybern, Kimberly Signs, Allison Zaldivar, Tom M. Chiller, Brendan R. Jackson, Orion McCotter
Journal: MMWR Morbidity and Mortality Weekly Report (2019)